Markus Graefen
University of Hamburg
CancerInternal medicineRadiologyUrologySurgeryOncologyStage (cooking)BiopsyProstateBiochemical recurrenceProstatectomyProstate cancerLymph nodeProstate-specific antigenGynecologyIn patientNomogramCancer researchMedicineCohort
1,254Publications
101H-index
24.2kCitations
Publications 1270
Newest
#1Analena HandkeH-Index: 1
#2Markus GraefenH-Index: 101
Last. Jan Philipp RadtkeH-Index: 19
view all 8 authors...
Source
#1Mykyta KachanovH-Index: 3
Last. Lars BudäusH-Index: 33
view all 10 authors...
PURPOSE We assessed whether sampling of the transitional zone can be spared in patients with exclusively peripheral prostate cancer (PCa)-suspicious multiparametric magnetic resonance imaging (mpMRI) lesions who undergo combined mpMRI targeted (TBx) and systematic prostate biopsies (SBx). MATERIALS AND METHODS Of 1,685 patients who underwent extended SBx including transitional zone sampling and had TBx of ≥1 lesion in the peripheral and/or transitional zone, we selected 863 patients with exclusi...
Source
#1Francesco Chierigo (UniGe: University of Genoa)H-Index: 8
#2M. Wenzel (UdeM: Université de Montréal)
Last. M. Gallucci (Policlinico Umberto I)H-Index: 2
view all 16 authors...
Purpose:Our goal was to compare cancer specific mortality (CSM) rates between radical prostatectomy (RP) vs external beam radiotherapy (EBRT) in National Comprehensive Cancer Network© (NCCN©) high ...
Source
#1Christoph Würnschimmel (UdeM: Université de Montréal)H-Index: 3
#2M. Wenzel (UdeM: Université de Montréal)
Last. Carlo Terrone (UniGe: University of Genoa)H-Index: 29
view all 15 authors...
Objectives null To test the effect of race/ethnicity on cancer-specific mortality after radical prostatectomy or external beam radiotherapy in localized prostate cancer patients. null Methods null In the Surveillance, Epidemiology and End Results database 2004-2016, we identified intermediate-risk and high-risk white (n = 151 632), Asian (n = 11 189), Hispanic/Latino (n = 20 077) and African American (n = 32 550) localized prostate cancer patients, treated with external beam radiotherapy or radi...
1 CitationsSource
#2Dmitry N. Pelageev (Far Eastern Federal University)H-Index: 5
Development of resistance to currently available standard therapies in advanced prostate cancer (PCa) emphasizes the need for novel therapeutic options. Here, we report the synthesis of new hybrid molecules consisting of 2-chloroethylthio and 1,4-naphthoquinone pharmacophores and describe their activity in PCa. In screening analyses, the introduction of one 2-chloroethylthio group improved the anticancer properties of 1,4-naphthoquinones, whereas the introduction of a second 2-chloroethylthio mo...
Source
#1Benedikt Hoeh (UdeM: Université de Montréal)H-Index: 2
#2Christoph Würnschimmel (UdeM: Université de Montréal)H-Index: 3
Last. M. Gallucci (Policlinico Umberto I)H-Index: 2
view all 18 authors...
INTRODUCTION Over the last decade, multiple clinical trials demonstrated improved survival after chemotherapy for metastatic prostate cancer (mPCa). However, real-world data validating this effect within large-scale epidemiological data sets are scarce. We addressed this void. MATERIALS AND METHODS Men with de novo mPCa were identified and systemic chemotherapy status was ascertained within the Surveillance, Epidemiology, and End Results database (2004-2016). Patients were divided between histor...
Source
#1M. Wenzel (UdeM: Université de Montréal)
#2Christoph Würnschimmel (UdeM: Université de Montréal)H-Index: 3
Last. Severine BanekH-Index: 2
view all 14 authors...
BACKGROUND To analyze postoperative, in-hospital, complication rates in patients with organ transplantation before radical prostatectomy (RP). METHODS From National Inpatient Sample (NIS) database (2000-2015) prostate cancer patients treated with RP were abstracted and stratified according to prior organ transplant versus nontransplant. Multivariable logistic regression models predicted in-hospital complications. RESULTS Of all eligible 202,419 RP patients, 216 (0.1%) underwent RP after prior or...
Source
Source
#1M. Wenzel (UdeM: Université de Montréal)
#2Marina Deuker (UdeM: Université de Montréal)H-Index: 5
Last. Derya Tilki (UHH: University of Hamburg)H-Index: 57
view all 0 authors...
Abstract null null Background null The efficacy of tyrosine kinase inhibitor (TKI)-based therapy after previous immuno-oncology therapy (IO) failure has been addressed before. However, summary efficacy estimates have never been generated in these reports. We addressed this void. null null null Material and methods null We systematically examined TKI efficacy after IO-failure and generated weighted median progression-free survival (PFS) estimates for Pazopanib, Axitinib, Cabozantinib, Sunitinib. ...
Source
#2Luigi NoceraH-Index: 5
Last. Hartwig HulandH-Index: 94
view all 12 authors...
Source